Clinical Trials · NCT06505395
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Enrollment
- 90
- Start date
- Jul 2024
- Locations
- 1 site, China
- Primary endpoint
- Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)